List view / Grid view
23 March 2015 | By Victoria White
GLYXAMBI® tablets are now available by prescription in the US. GLYXAMBI offers improved glycemic control as an adjunct to diet and exercise...
20 March 2015 | By Victoria White
The global treatment market for Type 1 Diabetes (T1D) will expand from $6.6 billion in 2013 to an estimated $13.6 billion by 2023 according to GlobalData...
19 March 2015 | By Victoria White
Sanofi announce top-line results of the Phase IIIb ELIXA cardiovascular outcomes study, comparing lixisenatide to placebo in adults with type 2 diabetes...
26 February 2015 | By Sanofi
The U.S. Food and Drug Administration (FDA) has approved Sanofi's Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insulin, to improve glycemic control in adults living with type 1 and type 2 diabetes...
24 February 2015 | By Merck KGaA
Merck, in collaboration with Maharashtra University and University of Indonesia, is introducing European Accredited Clinical Diabetes management for more than 5000 medical and pharmacy students of both universities as part of Merck Capacity Advancement Program in Asia...
23 February 2015 | By Persistence Market Research
North America has the largest market and Asia-Pacific has the fastest growing market for human insulin. In terms of type of human insulin, modern human insulin represents the largest and fastest growing segment of this market...
11 February 2015 | By Eli Lilly & Company
College freshmen face tremendous pressure, often trying to adjust to tough academic standards while living away from home for the first time...
9 February 2015 | By Roche
Roche announced that the U.S. Food and Drug Administration approved Lucentis® (ranibizumab injection) for the treatment of diabetic retinopathy, in people with diabetic macular edema...
6 February 2015 | By Merck
The 5 year program was kicked off successfully in Africa, India and Indonesia and will further expand to other African and Asian countries in 2015...
3 February 2015 | By Lilly Diabetes
Today Lilly Diabetes announced its support of the American Diabetes Association (Association) summer camp program by donating $92,000 for camp scholarships...
3 February 2015 | By Sanofi / MannKind Corporation
Sanofi and MannKind Corporation announced today that Afrezza® (insulin human) Inhalation Powder, the only inhaled insulin, is now available by prescription in U.S. retail pharmacies nationwide. Afrezza is approved by the U.S. Food and Drug Administration to control high blood sugar in adults with type 1 and type 2 diabetes...
3 February 2015 | By Eli Lilly
The U.S. FDA has approved Glyxambi® (empagliflozin/linagliptin) tablets, from Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2D) when both empagliflozin and linagliptin are appropriate treatments...
19 January 2015 | By Novo Nordisk
Novo Nordisk announced Switzerland as the first country to launch Xultophy® (IDegLira) for people with type 2 diabetes...
The newest GLP-1 receptor agonist treatment option to help improve glycemic control type 2 diabetes in adults is now available in U.S. pharmacies. Eli Lilly and Company's (LLY) Trulicity™ (dulaglutide) is a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) designed with patients in mind. It comes in a single-dose pen…
9 October 2014 | By Roche
Roche announced that the U.S. Food and Drug Administration has accepted to file the company's supplemental Biologics License Application and granted Priority Review of Lucentis (ranibizumab injection) for the treatment of diabetic retinopathy, an eye disease that impacts nearly 7.7 million Americans...
